| abstract |
Treatment of patients with angiogenesis in the eye, especially retinal edema, diabetic retinopathy, retinal ischemia-related sequelae, posterior ocular neovascularization (PSNV), and neovascular glaucoma, and develops such conditions For the purpose of treating at-risk patients, RNA interference is provided to suppress HIF1A mRNA expression. The present invention provides a method for attenuating HIF1A mRNA expression in a subject comprising a composition comprising an effective amount of an interfering RNA of 19-49 nucleotides in length and a pharmaceutically acceptable carrier. Administering to said subject. |